AMNEAL PHARMACEUTICALS, INC. Inventory, Finished Goods, Net of Reserves
AMNEAL PHARMACEUTICALS, INC. (AMRX) had Inventory, Finished Goods, Net of Reserves of $350.76 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Inventory, Net, Items Net of Reserve Alternative › Inventory, Finished Goods and Work in Process, Net of Reserves
us-gaap:InventoryFinishedGoodsNetOfReserves · last filed 2026-08-06
- 2026-06-30: Inventory, Finished Goods, Net of Reserves $350.76M.
- 2026-03-31: Inventory, Finished Goods, Net of Reserves $349.41M.
- 2025-12-31: Inventory, Finished Goods, Net of Reserves $323.49M.
- 2025-09-30: Inventory, Finished Goods, Net of Reserves $341.29M.
| Period end | Inventory, Finished Goods, Net of Reserves |
|---|---|
| 2026-06-30 | $350.76M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $349.41M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $323.49M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $341.29M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $342.67M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $335.21M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $351.92M 10-K · filed 2026-02-27 |
| 2024-09-30 | $323.04M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $326.76M 10-Q · filed 2024-08-09 |
| 2024-03-31 | $315.99M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $304.08M 10-K · filed 2025-02-28 |
| 2023-09-30 | $288.10M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $259.63M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $256.81M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $247.61M 10-K · filed 2024-03-14 |
| 2022-09-30 | $247.67M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $240.65M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $234.87M 10-Q · filed 2022-05-06 |
| 2021-12-31 | $227.08M 10-K · filed 2023-03-03 |
| 2021-09-30 | $263.11M 10-Q · filed 2021-11-08 |
| 2021-06-30 | $259.56M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $239.50M 10-Q · filed 2021-05-07 |
| 2020-12-31 | $240.53M 10-K · filed 2022-03-01 |
| 2020-09-30 | $237.19M 10-Q · filed 2020-11-06 |
| 2020-06-30 | $223.42M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $222.16M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $150.72M 10-K · filed 2021-03-01 |
| 2019-09-30 | $168.24M 10-Q · filed 2019-11-07 |
| 2019-06-30 | $196.06M 10-Q · filed 2019-08-05 |
| 2019-03-31 | $207.97M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $221.41M 10-K · filed 2020-03-02 |
| 2018-09-30 | $234.56M 10-Q · filed 2018-11-07 |
| 2018-06-30 | $250.56M 10-Q · filed 2018-08-09 |
| 2017-12-31 | $105.84M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |